A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs HMR-59 (Primary) ; Aflibercept; Bevacizumab; Prednisolone; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Sponsors Hemera Biosciences
- 03 Dec 2019 Planned End Date changed from 6 Feb 2020 to 6 Feb 2021.
- 06 Jan 2019 Planned number of patients changed from 10 to 25.
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.